In a report released today, Frank Takkinen from Lake Street maintained a Buy rating on Artivion (AORT – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $29.76.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Takkinen is an analyst with an average return of -0.3% and a 38.74% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as Stereotaxis, NeuroPace, and REPRO-MED Systems.
Artivion has an analyst consensus of Strong Buy, with a price target consensus of $32.50.
Based on Artivion’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $98.98 million and a GAAP net loss of $505 thousand. In comparison, last year the company earned a revenue of $97.43 million and had a net profit of $7.53 million
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AORT in relation to earlier this year. Earlier this month, ANTHONY B. SEMEDO, a Director at AORT sold 2,600.00 shares for a total of $74,022.00.
Read More on AORT:
- Artivion Completes Convertible Notes Exchange Agreement
- Artivion Shareholders Approve Directors and Compensation
- Artivion Announces Convertible Notes Exchange Agreement
- Artivion’s Earnings Call: Optimism Amid Challenges
- Artivion’s Strong Q1 Performance and Growth Prospects Justify Buy Rating Despite Challenges